Title: Board Member for the Diaspora Human Genomics Institute
Company: Meharry Medical College
Location: Basking Ridge, New Jersey, United States
Dr. Frank L. Douglas, PhD, MD, Board Member for the Diaspora Human Genomics Institute at Meharry Medical College, has been recognized by Marquis Who’s Who Top Doctors for dedication, achievements, and leadership in medical science.
Dr. Douglas has established an esteemed career marked by significant contributions to both the pharmaceutical industry and academia. Currently, he excels as a board member of the Diaspora Human Genomics Institute at Meharry Medical College, where he plays a pivotal role in advancing diversity in genomic research. This initiative aims to address the underrepresentation of Black individuals in genomic studies by developing comprehensive genomic profiles of Black populations and other underrepresented minorities. Dr. Douglas’s involvement underscores his ongoing commitment to ensuring broader inclusion in medical research and innovation.
In addition to his position at Meharry Medical College, Dr. Douglas has found success as the chief executive officer of Safe Haven Dialogues LLC, which he has held since 2020. Through this platform, he leads workshops titled “Reframe for Resilience.” His primary work focuses on helping individuals and organizations navigate situations involving discrimination and bias, teaching participants how to identify broader issues that affect more than just the individual. By addressing problems that others also experience, Dr. Douglas helps foster collective efforts and alliances.
Dr. Douglas’s expertise in pharmaceutical innovation is further demonstrated through his role as scientific advisor and chairman of the scientific advisory board at EOM Pharmaceuticals, Inc., a position he has held since 2021. Additionally, he serves as the vice president of real world clinical research and outcomes at the Center for Medicine in the Public Interest, where he has been contributing since 2020. His technical acumen is also recognized through his advisory role with XaTek, now known as ClotChip, since 2018.
Dr. Douglas’s career trajectory includes notable leadership positions within the pharmaceutical industry. He was active for a decade as senior vice president and head of research for Ciba-Geigy, which later became Novartis. He then worked as the executive vice president, board member and global head of research and development for Marion Merrell Dow before its acquisition by Hoechst AG. His tenure culminated as an executive vice president and board member of Aventis, now Sanofi, before retiring in 2004. His groundbreaking innovations have led to the development and commercialization of over 25 drugs designed to treat complex diseases.
Dr. Douglas’s academic journey began with a Bachelor of Science in chemistry from Lehigh University in 1966, followed by a Doctor of Philosophy in physical chemistry and a Doctor of Medicine from Cornell University in 1977. His education laid the foundation for his success, driven by perseverance and resilience cultivated during his formative years in British Guiana. He further obtained certifications in diversity, equity and inclusion from eCornell at Cornell University in 2022 and investing in human skills in the age of AI from LinkedIn Learning in 2024.
Throughout his distinguished career, Dr. Douglas has been recognized with numerous accolades, including being honored as the Global Pharmaceutical R&D Director of the Year twice and receiving the Rockstar of Science Award from the Geoffrey Beene Foundation and GQ Magazine/Condé Nast in 2010. He is also an accomplished author with publications such as “Finding Moments of a Free Man from a Black Screen” in 2018 and “Until You Walk in My Shoes: Reframe Methodology” in 2022. As a podcast host for “Reframe For Resilience,” Dr. Douglas continues to share his insights on problem-solving methodologies.
Dr. Douglas’s personal mission is deeply rooted in reframing—a strategy that has contributed significantly to his success as an innovator. He views challenges as opportunities to shift perspectives and find new solutions across various disciplines. His goal in the coming years is to share this approach widely, particularly in social contexts where challenges are increasingly complex, encouraging others to see difficulties as opportunities for rethinking and resolving systemic problems.
For more information, please visit:
LinkedIn
Safe Haven Dialogues
Contact Dr. Douglas:
